Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection
- PMID: 2843483
Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection
Abstract
A panel of well characterized monoclonal antibodies (MAbs) directed against outer membrane proteins H2, or F (porin) of Pseudomonas aeruginosa were examined to determine whether they exhibited any protective effect against subsequent ocular challenge with the bacteria topically applied to the scarified corneal surface. Mice were observed macroscopically following bacterial challenge and the degree of ocular disease graded on a scale of 0 to 4 (0, normal, fully protected cornea; 4, corneal perforation or phthisis, not protected). Mice treated intravenously with either MAb MA1-6 (anti-H2) or MA2-10 (anti-F), or a combination of these two MAbs and MAb MA4-4 (anti-F), two hours before corneal challenge with the viable bacteria, exhibited significantly less corneal disease than mice either not treated with the MAbs, treated with MA4-4 alone or treated with MAb MA1-3 (anti-I). The latter MAb is directed against an outer membrane epitope that is not surface exposed. Light and transmission electron microscopic histopathology also was employed and provided confirmatory evidence to support the macroscopic analyses.
Similar articles
-
Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.Invest Ophthalmol Vis Sci. 1997 Jun;38(7):1418-25. Invest Ophthalmol Vis Sci. 1997. PMID: 9191605
-
Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.Biomed Pept Proteins Nucleic Acids. 1995;1(3):141-8. Biomed Pept Proteins Nucleic Acids. 1995. PMID: 9346845
-
Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.Behring Inst Mitt. 1994 Dec;(95):85-96. Behring Inst Mitt. 1994. PMID: 7538752
-
Secretory IgA inhibits Pseudomonas aeruginosa binding to cornea and protects against keratitis.Invest Ophthalmol Vis Sci. 1997 Apr;38(5):910-8. Invest Ophthalmol Vis Sci. 1997. PMID: 9112987
-
Pathogenesis of Pseudomonas aeruginosa ocular diseases.Rev Infect Dis. 1983 Nov-Dec;5 Suppl 5:S931-5. doi: 10.1093/clinids/5.supplement_5.s931. Rev Infect Dis. 1983. PMID: 6419316 Review.
Cited by
-
Animal models of bacterial keratitis.J Biomed Biotechnol. 2011;2011:680642. doi: 10.1155/2011/680642. Epub 2011 Jan 4. J Biomed Biotechnol. 2011. PMID: 21274270 Free PMC article. Review.
-
Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa.Infect Immun. 1992 Sep;60(9):3497-503. doi: 10.1128/iai.60.9.3497-3503.1992. Infect Immun. 1992. PMID: 1379985 Free PMC article.
-
Use of synthetic peptides to identify surface-exposed, linear B-cell epitopes within outer membrane protein F of Pseudomonas aeruginosa.Curr Microbiol. 1995 Nov;31(5):279-86. doi: 10.1007/BF00314580. Curr Microbiol. 1995. PMID: 7580798
-
Kinetics of serum and ocular antibody responses in susceptible mice that received a secondary corneal infection with Pseudomonas aeruginosa.Infect Immun. 1993 Jun;61(6):2713-6. doi: 10.1128/iai.61.6.2713-2716.1993. Infect Immun. 1993. PMID: 8500912 Free PMC article.
-
Development of an anti-Pseudomonas aeruginosa therapeutic monoclonal antibody WVDC-5244.Front Cell Infect Microbiol. 2023 Apr 14;13:1117844. doi: 10.3389/fcimb.2023.1117844. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37124031 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical